Aqr Capital Management LLC Eye Point Pharmaceuticals, Inc. Transaction History

Aqr Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$8.16 - $22.89 $247,680 - $694,780	-30,353 Reduced 51.38%	28,723 $249,000
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $693,723 - $1.03 Million	34,808 Added 143.43%	59,076 $1.22 Million
Q4 2023 Feb 14, 2024	BUY	$5.71 - $24.13 $51,047 - $215,722	8,940 Added 58.32%	24,268 $560,000
Q3 2023 Nov 14, 2023	BUY	$7.99 - $15.36 $122,470 - $235,438	15,328 New	15,328 $122,000
Q2 2022 Aug 15, 2022	BUY	$7.25 - $12.71 $2,044 - $3,584	282 Added 2.07%	13,921 $110,000
Q1 2022 May 16, 2022	SELL	$8.67 - $14.11 $10,499 - $17,087	-1,211 Reduced 8.15%	13,639 $166,000
Q4 2021 Feb 14, 2022	BUY	$10.18 - $18.4 $151,173 - $273,240	14,850 New	14,850 $182,000

156

72.4M

187K

225K

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $214M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.